Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
EMD Serono executes amendment agreement with Opexa for development of Tcelna (imilecleucel-T)

EMD Serono executes amendment agreement with Opexa for development of Tcelna (imilecleucel-T)

EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T). [More]
M-MDSCs may be effective in treating arthritis in humans

M-MDSCs may be effective in treating arthritis in humans

Using a mouse model of rheumatoid arthritis, scientists have discovered that a form of cellular immunotherapy by intravenous administration of monocytic myeloid-derived suppressor cells, or M-MDSCs, might be an effective treatment for the disease in humans. [More]
CPRIT awards research and recruitment grants to improve cancer research

CPRIT awards research and recruitment grants to improve cancer research

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center researchers more than $7.5 million in research grants to improve diagnostic and therapeutic services and research relating to cancers of the brain, breast, throat, and bone, as well as to improve scientific understanding of cancer biology. [More]
LUNGevity applauds FDA's approval of Opdivo drug

LUNGevity applauds FDA's approval of Opdivo drug

LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells. [More]
Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

Asterias Biotherapeutics, Inc., a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation's top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI). [More]
New approach could dramatically increase survival rate of cancer patients

New approach could dramatically increase survival rate of cancer patients

Michail Sitkovsky, an immunophysiology expert at Northeastern University, and his research colleagues have made a breakthrough discovery in cancer treatment. The new approach, some 30 years in the making, could dramatically increase the survival rate of patients with cancer, which kills some 8 million people each year. [More]
Changing breast cancer cells' shape could make the disease more sensitive to treatments

Changing breast cancer cells' shape could make the disease more sensitive to treatments

Changing the shape of breast cancer cells could make the disease more sensitive to treatments - even driving the body's own inflammatory response against a tumour - a new study shows. [More]
Study: Pregnant women need to avoid antibiotics to prevent asthma development in children

Study: Pregnant women need to avoid antibiotics to prevent asthma development in children

Getting sick when you're pregnant is especially difficult, but women whose children are at risk for developing asthma should avoid antibiotics, according to a new study. [More]
New article shows how marijuana can act as an allergen

New article shows how marijuana can act as an allergen

Growing up, you may have been given reasons for not smoking marijuana. What you may not have heard is that marijuana, like other pollen-bearing plants, is an allergen which can cause allergic responses. [More]
Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen. [More]

TxCell invited to speak at largest US meeting for investors in emerging growth companies

In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference. [More]
New test can predict survival chances of women with breast cancer

New test can predict survival chances of women with breast cancer

Scientists have developed a new test which can predict the survival chances of women with breast cancer by analysing images of 'hotspots' where there has been a fierce immune reaction to a tumour. [More]
Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). [More]
MD Anderson awarded more than $22 million in research grants from CPRIT

MD Anderson awarded more than $22 million in research grants from CPRIT

The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas. Approximately half of the funds awarded for Individual Investigator Research Awards went to MD Anderson faculty as well as 40 percent of total IIRA awards that include those for children's and adolescent cancer and early detection and prevention. [More]
Study results pave way for new clinical trial for glioblastoma patients

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research. [More]
NYU Langone, Technion collaborate to advance cancer research

NYU Langone, Technion collaborate to advance cancer research

In a groundbreaking step forward to advance global collaboration in the fight against cancer, two of the world's preeminent academic and research institutions -- NYU Langone Medical Center and the Technion-Israel Institute of Technology -- formally announced a $9 million gift from philanthropists Laura and Isaac Perlmutter that will fund two major, joint research endeavors with potentially far-reaching impact in advancing cancer research. [More]
FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec. [More]
Discovery improves understanding of factors that trigger allergic asthma

Discovery improves understanding of factors that trigger allergic asthma

When the mucosal surfaces in the lungs of healthy people come into contact with allergenic substances, so-called regulatory T cells also known as Treg cells, are activated. These are capable of actively preventing the development of allergies. [More]
Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China. [More]
RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone with Hapten Pharmaceuticals, LLC. [More]
Advertisement
Advertisement